Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, et al.
Cancer Treatment Reviews (2021) Vol. 95, pp. 102170-102170
Open Access | Times Cited: 135

Showing 26-50 of 135 citing articles:

Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging
Marina Baretti, Soumya Shekhar, Vaibhav Sahai, et al.
Hepatology Communications (2025) Vol. 9, Iss. 3
Open Access
Molecular signatures of intrahepatic Cholangiocarcinoma: Role in targeted therapy selection
Tetiana Glushko, James Costello, Ranjit S. Chima, et al.
European Journal of Radiology (2025), pp. 112056-112056
Closed Access
CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma
Yu Huang, Yulu Ye, Tingzhuang Yi, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
Su Min Cho, Abdullah Esmail, Ali Raza, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2641-2641
Open Access | Times Cited: 21
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives
Davide Ciardiello, Brigida Anna Maiorano, Paola Parente, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 820-820
Open Access | Times Cited: 19
MUC1 induces the accumulation of Foxp3+ Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway
Guofeng Zhang, Zheng Ge, Haipeng Zhang, et al.
International Immunopharmacology (2023) Vol. 118, pp. 110091-110091
Closed Access | Times Cited: 12
Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma
Timothy P. DiPeri, Ming Zhao, Kurt W. Evans, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 2, pp. 322-334
Closed Access | Times Cited: 12
Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
Ying Zhang, Ran Li, Yongchao Liang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 11
Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways
Rattanaporn Jaidee, Veerapol Kukongviriyapan, Laddawan Senggunprai, et al.
Life Sciences (2022) Vol. 296, pp. 120427-120427
Closed Access | Times Cited: 18
FGFR Inhibitors in Cholangiocarcinoma—A Novel Yet Primary Approach: Where Do We Stand Now and Where to Head Next in Targeting This Axis?
Paulina Chmiel, Katarzyna Gęca, Karol Rawicz‐Pruszyński, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3929-3929
Open Access | Times Cited: 18
Precision Oncology Targets in Biliary Tract Cancer
Nicole Farha, Danai Dima, Fauzia Ullah, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2105-2105
Open Access | Times Cited: 10
FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies
Yutaka Fujiwara, Yasutoshi Kuboki, Masayuki Furukawa, et al.
Cancer Medicine (2023) Vol. 12, Iss. 9, pp. 10597-10611
Open Access | Times Cited: 9
Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma
Chunbin Zhu, Jiaqiang Ma, Kai Zhu, et al.
JHEP Reports (2023) Vol. 5, Iss. 8, pp. 100762-100762
Open Access | Times Cited: 9
Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1–3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment
Song Liao, Jianxiong Li, Song Gao, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials
Qichuan Deng, Yü Huang, Jing Zeng, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117343-117343
Open Access | Times Cited: 3
Precision medicine: an intrahepatic cholangiocarcinoma with a novel RBPMS-MET fusion sensitive to crizotinib
Wei Wan, Xueqin Liu, Yamin Zhang, et al.
The Oncologist (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 3
Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies
Alexandra W. Acher, Alessandro Paro, Ahmed Elfadaly, et al.
Cancers (2021) Vol. 13, Iss. 20, pp. 5169-5169
Open Access | Times Cited: 22
Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management
Sakti Chakrabarti, Heidi D. Finnes, Amit Mahipal
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 1, pp. 85-98
Closed Access | Times Cited: 15
Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision
Yuqi Zhang, Abdullah Esmail, Vincenzo Mazzaferro, et al.
Cancers (2022) Vol. 14, Iss. 20, pp. 5074-5074
Open Access | Times Cited: 15
Precision Medicine Targeting FGFR2 Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives
Miguel Zugman, Gehan Botrus, Roberto Carmagnani Pestana, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 14
Advances in the systemic treatment of therapeutic approaches in biliary tract cancer
Oriol Mirallas, D. López-Valbuena, David García-Illescas, et al.
ESMO Open (2022) Vol. 7, Iss. 3, pp. 100503-100503
Open Access | Times Cited: 14
Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma
Zhanqi Wei, Yajing Wang, Boyang Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Locoregional Approaches in Cholangiocarcinoma Treatment
Alexander E. Hare, Mina S. Makary
Cancers (2022) Vol. 14, Iss. 23, pp. 5853-5853
Open Access | Times Cited: 12
FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice
Valentina Angerilli, Lorenzo Fornaro, Francesco Pepe, et al.
Pathologica (2023) Vol. 115, Iss. 2, pp. 71-82
Open Access | Times Cited: 7
γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus
Charupong Saengboonmee, Supannika Sorin, Sakkarn Sangkhamanon, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 28, pp. 4416-4432
Open Access | Times Cited: 7

Scroll to top